Overview

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is a biphasic steady state pharmacokinetic and pharmacodynamic study of TFV and FTC in healthy women comparing the drug levels and activity in the absence (first phase) and then the presence (second phase) of DMPA. The investigators will recruit 12 healthy women aged 18-45 who are HIV-negative and at low risk for acquiring HIV.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jessica Tarleton
Sharon Achilles
Treatments:
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Medroxyprogesterone
Medroxyprogesterone Acetate
Tenofovir